Literature DB >> 1971329

Autotransplants in chronic myelogenous leukaemia: strategies and results.

A Butturini1, A Keating, J Goldman, R P Gale.   

Abstract

Autotransplants are increasingly used in chronic myelogenous leukaemia (CML). Most are performed in advanced leukaemia; now, autotransplants in chronic phase are being evaluated. Treatment involves high-dose chemotherapy with or without radiation followed by a transplant of previously cryopreserved stem cells derived from bone marrow or blood. The transplanted bone marrow may be manipulated in vitro to remove CML cells. Results vary. Transplants in advanced CML usually re-establish chronic phase but responses are brief. After transplants in chronic phase some recipients become Philadelphia chromosome negative for a year or more; others remain Ph-chromosome positive. There are insufficient data to show whether these early transplants prolong chronic phase duration or increase survival. The incurability of CML by conventional therapy should encourage further studies of this approach.

Entities:  

Mesh:

Year:  1990        PMID: 1971329     DOI: 10.1016/0140-6736(90)91313-y

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  5 in total

Review 1.  Autografting as first line treatment for chronic myeloid leukaemia.

Authors:  I O Singer; I M Franklin
Journal:  J Clin Pathol       Date:  1998-02       Impact factor: 3.411

2.  The scientific bases of cancer management: at the interface between fundamental research and clinical practice.

Authors:  M Tubiana
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

3.  Expression of BCR/ABL and BCL-2 in myeloid progenitors leads to myeloid leukemias.

Authors:  Siddhartha Jaiswal; David Traver; Toshihiro Miyamoto; Koichi Akashi; Eric Lagasse; Irving L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-30       Impact factor: 11.205

4.  Persistence of bcr-abl mRNA-expressing cells in long-term cultures established from chronic myeloid leukemic bone marrow or blood.

Authors:  G Pasternak; L Pasternak
Journal:  Ann Hematol       Date:  1994-01       Impact factor: 3.673

Review 5.  Cytokines and bone marrow transplantation.

Authors:  F Takaku
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.